Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
Hoffmann-La Roche
Othman Al-Sawaf; Can Zhang; Tong Lu; Michael Z Liao; Anesh Panchal; Sandra Robrecht; Travers Ching; Maneesh Tandon; Anna-Maria Fink; Eugen Tausch; Christof Schneider; Matthias Ritgen; Sebastian Böttcher; Karl-Anton Kreuzer; Brenda Chyla; Dale Miles; Clemens-Martin Wendtner; Barbara Eichhorst; Stephan Stilgenbauer; Yanwen Jiang; Michael Hallek; Kirsten Fischer